DelveInsight’s, \"Myelodysplastic Syndrome Pipeline Insights 2025\" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the Myelodysplastic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelodysplastic Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.\n\nDownload our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry!\n\nKey Takeaways from the Myelodysplastic Syndrome Pipeline Report\n\nIn August 2025, Novartis Pharmaceuticals announced a study is designed to evaluate the efficacy and safety of eltrombopag monotherapy in Japanese adult patients with platelet transfusion-dependent lower-risk Myelodysplastic syndromes (LR-MDS). In August 2025, H. Lee Moffitt Cancer Center and Research Institute conducted a study is a multi-institution, open-label, Phase 1b/2 clinical trial evaluating the toxicity and efficacy of canakinumab in combination with darbepoetin alfa in patients with lower-risk MDS who have failed prior treatment with an Erythropoietin Stimulating Agent (ESA). DelveInsight’s Myelodysplastic Syndrome pipeline report depicts a robust space with 120+ active players working to develop 150+ pipeline therapies for Myelodysplastic Syndrome treatment. The leading Myelodysplastic Syndrome Companies such as Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals and others. Promising Myelodysplastic Syndrome Therapies such as Deferasirox, Bortezomib, Decitabine and cedazuridine, Luspatercept, Epoetin Alfa, and others.\n\nLearn how leading Myelodysplastic Syndrome Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!\n\nMyelodysplastic Syndrome Emerging Drugs Profile\n\nTamibarotene: Syros Pharmaceuticals\nTamibarotene (formerly SY-1425) is an oral selective retinoic acid receptor alpha (RARα) agonist. The company is developing treatments for genomically defined subsets of patients whose disease is characterized by the overexpression of the RARA gene. Approximately 50% of MDS patients and 30% of AML patients have RARA overexpression. When RARα is expressed in excess of its tightly controlled natural ligand, cells in the bone marrow may not differentiate into healthy myeloid cells, which can lead to hematological malignancies. However, when oral tamibarotene is administered, tamibarotene binds to RARα, allowing for the restoration of gene expression and myeloid differentiation. The company is currently investigating tamibarotene in the Phase III SELECT-MDS-1 trial in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA overexpression.\n\nRVU120: Ryvu Therapeutics\nRVU120 (SEL120) is a specific, selective inhibitor of CDK8 and its paralog, CDK19. Preclinical studies indicated the strong antileukemic potential of RVU120, which was often associated with the multilineage commitment of CD34+ AML cells. Moreover, RVU120 could improve proliferation and induce erythroid differentiation of CD34+ cells derived from Diamond-Blackfan anemia (DBA) patients. Currently, the drug is in the Phase II stage of its development for the treatment of Myelodysplastic syndromes.\n\nEmavusertib: Curis\nEmavusertib, which is being developed by Curis, is a small-molecule IRAK4 kinase inhibitor. Inhibition of IRAK4-L activity with emavusertib (CA-4948) blocks leukemic growth in non-clinical experiments. Because IRAK4 plays a central role in this pathway, it is considered an attractive target for the generation of therapeutics to treat these B-cell malignancies as well as certain inflammatory diseases. As part of the collaboration with Aurigene, in October 2015, Curis exclusively licensed a program of orally available, small molecule inhibitors of IRAK4 kinase, including emavusertib (CA-4948). Currently, the drug is in the Phase I/II stage of its development for the treatment of Myelodysplastic syndromes.\n\nMNV-201: Minovia Therapeutics\nMNV-201 is an investigational cell therapy developed by Minovia Therapeutics, targeting low-risk Myelodysplastic Syndromes (MDS). It utilizes a novel approach known as Mitochondrial Augmentation Technology (MAT), which involves enriching a patient's own hematopoietic stem and progenitor cells (HSPCs) with mitochondria derived from allogeneic placental sources. This therapy aims to address mitochondrial dysfunction, which is implicated in the pathophysiology of MDS. Currently, MNV-201 is undergoing a Phase I clinical trial (NCT06465160) that is actively recruiting participants. The study's primary objective is to evaluate the safety and therapeutic effects of MNV-201 in patients diagnosed with low-risk MDS.\n\nThe Myelodysplastic Syndrome Pipeline report provides insights into the following:\n- Detailed insights about companies that are developing therapies for the treatment of Myelodysplastic Syndrome with aggregate therapies developed by each company for the same.\n- Access to different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelodysplastic Syndrome Treatment.\n- Myelodysplastic Syndrome Companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.\n- Myelodysplastic Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.\n- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myelodysplastic Syndrome market.\n\nFrom early-stage research to late-phase Myelodysplastic Syndrome Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs—Download now!\n\nMyelodysplastic Syndrome Companies\nNovartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others.\n\nMyelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral, Intravenous, Subcutaneous, Parenteral, Topical.\n\nMyelodysplastic Syndrome Products have been categorized under various Molecule types such as Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy.\n\nStay updated with the latest Myelodysplastic Syndrome Pipeline Insights!\n\nScope of the Myelodysplastic Syndrome Pipeline Report\n- Coverage: Global\n- Myelodysplastic Syndrome Companies: Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others.\n- Myelodysplastic Syndrome Therapies: Deferasirox, Bortezomib, Decitabine and cedazuridine, Luspatercept, Epoetin Alfa, and others.\n- Myelodysplastic Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination\n- Myelodysplastic Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III\n\nDive deep into rich insights for new drugs for Myelodysplastic Syndrome Treatment, visit the report.\n\nTable of Content\n- Introduction\n- Executive Summary\n- Myelodysplastic Syndrome: Overview\n- Pipeline Therapeutics\n- Therapeutic Assessment\n- Myelodysplastic Syndrome– DelveInsight’s Analytical Perspective\n- Late Stage Products (Phase III)\n- Tamibarotene: Syros Pharmaceuticals\n- Mid Stage Products (Phase II)\n- CA-4948: Curis\n- Early Stage Products (Phase I)\n- MNV-201: Minovia Therapeutics\n- Preclinical and Discovery Stage Products\n- Drug name: Company name\n- Inactive Products\n- Myelodysplastic Syndrome Key Companies\n- Myelodysplastic Syndrome Key Products\n- Myelodysplastic Syndrome- Unmet Needs\n- Myelodysplastic Syndrome- Market Drivers and Barriers\n- Myelodysplastic Syndrome- Future Perspectives and Conclusion\n- Myelodysplastic Syndrome Analyst Views\n- Myelodysplastic Syndrome Key Companies\n- Appendix\n\nAbout Us\nDelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.\n\nMedia Contact\nCompany Name: DelveInsight Business Research LLP\nContact Person: Yash Bhardwaj\nEmail: Send Email\nPhone: 09650213330\nAddress: 304 S. Jones Blvd #2432\nCity: Las Vegas\nState: NV\nCountry: United States\nWebsite: https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight\n\nPress Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Myelodysplastic Syndrome Pipeline Outlook Report 2025: Key 120+ Companies and Breakthrough Therapies Shaping the Future Landscape

Myelodysplastic Syndrome Pipeline Outlook Report 2025: Key 120+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's 2025 Myelodysplastic Syndrome (MDS) Pipeline Report provides a comprehensive analysis of 120+ companies and 150+ pipeline therapies in the MDS treatment space. The report covers clinical and nonclinical stage drug developments, including therapies in phases I, II, and III, by product type, route of administration, and molecular mechanism. It highlights key companies such as Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, and Minovia Therapeutics, detailing their pipeline drugs like tamibarotene, RVU120, emavusertib, and MNV-201. The report also outlines ongoing clinical trials, including a Phase 1b/2 study by H. Lee Moffitt Cancer Center evaluating canakinumab with darbepoetin alfa in lower-risk MDS patients, and a Phase III trial by Syros Pharmaceuticals for tamibarotene in higher-risk MDS. Additionally, it details collaborations, therapeutic assessments, and inactive pipeline products, offering insights into market trends, unmet needs, and future directions in MDS treatment.